Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Research

Background:

• Eicosanoids derived from arachidonic acid (AA) play critical roles in regulating cerebral vascular tone and blood flow.
• Cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes metabolize AA into various eicosanoids implicated in cardiovascular diseases and stroke.
• COX-2 inhibitors, while explored for stroke treatment, carry risks, including increased stroke incidence with long-term use.

Purpose of the Study:

• To summarize recent findings on eicosanoid pathways in cerebral vascular function and stroke.
• To discuss the potential of targeting specific eicosanoid pathways for stroke treatment.
• To highlight the development of animal models for investigating these pathways.

Main Methods:

• Review of recent scientific literature on eicosanoid metabolism and stroke.
• Analysis of studies involving cyclooxygenase (COX) and cytochrome P450 (CYP) pathways.
• Examination of research utilizing animal models with targeted gene deletion and enzymatic inhibitors.

Main Results:

• Prolonged use of certain COX inhibitors increases 20-hydroxyeicosatetraenoic acid (20-HETE) levels, suggesting 20-HETE blockade as a strategy against coxib-induced stroke.
• 20-HETE blockade demonstrates cerebroprotective effects against ischemic stroke and subarachnoid hemorrhage (SAH).
• Activation of EP2 and EP4 receptors and stabilization of epoxyeicosatrienoic acids (EETs) via soluble epoxide hydrolase (sEH) inhibition show cerebroprotection in stroke models.

Conclusions:

• Eicosanoid pathways are crucial in cerebral vascular regulation and stroke pathogenesis.
• Targeting 20-HETE and epoxyeicosatrienoic acids (EETs) offers potential therapeutic strategies for ischemic stroke and SAH.
• Further research using advanced animal models is essential to identify effective targets for stroke treatment.